Reuters logo
BRIEF-Aveo Oncology announces phase 1/2 tinivo trial
2017年6月8日 / 上午11点19分 / 4 个月前

BRIEF-Aveo Oncology announces phase 1/2 tinivo trial

June 8 (Reuters) - Aveo Pharmaceuticals Inc:

* Aveo Oncology announces phase 1/2 tinivo trial of tivozanib and opdivo® (nivolumab) in RCC advances to phase 2

* Aveo Pharmaceuticals - “Registration strategy for single agent tivozanib reaches key inflection points, with European regulatory decision expected in near-term”

* Aveo - if registration strategy for single agent tivozanib reaches key inflection points, readout of us registration-directed tivo-3 study expected in Q1 of 2018 Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below